Tetra Bio-Pharma Inc. Strengthens Senior Management Team
Momentum Public Relations
Press Release: June 5 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX-V:TBP) (OTCQB:TBPMF), has strengthened its management team with the promotion of V.P. Financing and Business Development Robert (Bob) Bechard to Executive Vice President, Corporate Development and Licensing, and the hiring of Ofer Yifrach-Stav as Vice President Pharmaceutical Compliance and Quality.
In his new expanded role, Bob will lead Tetra Bio-Pharma’s business development and be actively involved in fundraising and executing the Company’s M&A strategy, while overseeing Investor Relations.
Bob has more than 25 years’ experience in financing, including venture capital and corporate banking along with business development. He was a Senior Member of a Venture Capital fund that delivered top quartile returns investing in North American Biotech companies. During his venture days, he served on the Boards of more than 30 biotech companies and oversaw the negotiation of numerous strategic alliances with major pharmaceutical companies. Additionally, he managed numerous exits via the public market or an outright sale to large pharmaceutical companies on behalf of the venture capital funds. Bob brings sound operational experience from his time as Chief Business Officer for an R&D Management company and VP of Corporate Development for a drug delivery company. As a consultant, he assisted numerous biotech companies in the areas of fundraising, business development, corporate development and strategy.
“We are thrilled to have Bob as an integral member of Tetra Bio-Pharma’s Senior Executive team. His vast experience and extensive international network will help drive the execution of our corporate strategy,” said Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.
“I am excited to be able to play a more active role in helping Tetra Bio-Pharma realize its vision to make pharmaceutical grade cannabinoid-based products accessible to patients around the world,” said Bob Bechard, EVP, Corporate Development and Licensing.
The new Vice President Pharmaceutical Compliance and Quality, Ofer Yifrach-Stav has extensive experience in pharmaceutical and medical device industries where he worked with major medical device, pharmaceutical and cosmetic companies in North America, Europe and Asia. During this time, he successfully lead the preparation of companies for Quality Audits by Health Canada, FDA, EU and Israeli Ministry of Health. Over the years he developed expertise in production process validations and other areas of quality assurance.
“Ofer Yifrach-Stav will play a key role in accelerating our pre-commercial activities in preparation of the marketing applications of PPP001 and PPP002. These activities include production scale-up activities and process validations required to ensure the completeness of the Quality file required for the marketing applications leading to the DIN,” added Guy Chamberland.
The corporation will be restructured to optimize operations by commercial markets. Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization. Tetra Veterinary Health was created for the commercialization of cannabinoid-based products for the pet product market. To take advantage of the post-legalization market, Tetra Natural Health was established to develop and sell cannabinoid-based OTC (self-care) products.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its vision, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Tetra Bio Pharma
Arctic Star Reports Positive Results in Finland: Best Diamond Results Found in Finland
Momentum Public Relations
Blog: June 4 2018
Diamonds Are Forever
Arctic Star Reports Positive Results in Finland: Best Diamond Results Found in Finland
Monster Diamonds found by Lucara
The surprising thing about diamonds is that people pay so much for them. The price was controlled for a very long time by De Beers which prevented too many diamonds from hitting the market at the same time to keep the price up.
De Beers also controlled diamond marketing and so is also responsible for that ubiquitous slogan, Diamonds are Forever.
The value of diamonds benefits from a superb marketing effort that has lasted for generations and convinced much of the global middle and upper classes that diamonds are the only way to express your love.
And then there is the lasting effect of Marilyn Munro singing “Diamonds Are a Girl’s Best Friend,” in the movie version of Gentlemen Prefer Blondes.
For something which is really only valuable as an industrial cutting tool, diamonds have secured an emotional value that has captured and held the imagination for a very long time. Diamonds show no indication of losing the monetary value associated with them.
Over the recent past the diamond market has been in a bit of a doldrum as millennials with cash to burn look to other luxury items. This will probably become just a market blip lasting as long as it takes the marketing machine to get revved up again. Then again, that may not be necessary. In a January 8, 2018 report the CBC quoted diamond analyst Paul Zimnisky predicting that the price of rough diamonds will increase by as much as four percent this year.
Unlike copper, gold or silver which regularly go in and out of high demand and high value cycles, as a commodity diamonds just appear to sit there looking pretty with an almost constant value, going up or down in cost in the low single digits.
This year, 2018, may just go down in the history books as the monster year of enormous diamond finds. On April 26, 2018 Bloomberg News reported in a headline: Another Week and Another Huge Diamond Is Found in Botswana.
The story reports that Lucara Diamond has just discovered a 327 carat white diamond at its mine in Botswana, hard on the heels of discovering a 427 carat light brown one. In comparison, most diamonds used in jewelry are in the one to two carat range.
Last year, Lucara sold a 1,109 carat diamond, the second biggest so far discovered for US$53 million. Last year Lucara also sold an 813 carat diamond for US$63 million. Lucara is not alone. Gem Diamonds Ltd. discovered a 910 carat diamond in Lesotho this year that it has already sold for US$40 million.
Along their way to the marriage ceremony or engagement party diamonds took a detour when they became the preferred way of financing murder and mayhem in Africa. This stigma has been done away with by the development and continuing exploration of diamond fields in Canada and Russia.
If matters pan out those productive diamond fields will soon be joined by the Timantti Diamond Project in Finland. Canadian junior Arctic Star Exploration has assembled a dream team of diamond finders who believe that the diamond rich Russian pipes extend into Finland and recent exploration results back up this theory.
There is a certain amount of wisdom in adages and folk sayings. In mining there is the one that goes, “The best place to find a gold mine is next to a gold mine.” This can be followed up by saying that the best person to find a diamond mine is someone who has found one before. Arctic Star’s exploration team is run by two of the most experienced diamond finders now working. Among other discoveries Buddy Doyle found the Diavik diamond mine in Northern Canada and Roy Spencer discovered the Grib diamond mine in Russsia. Both are multi-billion dollar mines.
In an April 16, 2018 press release Arctic Star’s Vice-President of Exploration Buddy Doyle said, “We are greatly encouraged by the results, to date. So far every kimberlite we have discovered on the Timantti property has proven to be diamondiferous. We are particular pleased by the results from the Wolves, as demonstrated from table 3, these are the best diamond results to date ever reported from Finland, at least at this initial discovery phase. We look forward to adding to this as the diamond results from our drilling become available.”
Arctic Star has a 100% interest in the 243 hectare Timantti property and exclusive exploration rights for two years on a further 95,700 hectares. The Finnish property is in the same geological belt as both the Russian multi-billion dollar Grib and Lomonsov diamond mines. The company is well financed and just finished an over-subscribed private placement for more than a million dollars.
To further pique your interest in Arctic Star, the company is far from being a one trick pony. It has three more highly prospective diamond projects in the Canadian north, the Diagras project, a joint venture with Margaret Lake, located close to and in the same geological formations as the multi-billion dollar Diavik diamond mine, the 100% owned Stein Diamond Project which has six drill ready targets and Redemption, which is close to the two major discoveries, Ekati and Diavik, that sparked the Canadian diamond exploration rush.
Just for variety, along with its four diamond projects Arctic Star also has a rare earth elements project in British Columbia called Cap. One way or another the odds appear stacked in Arctic Star’s favour.
- Published in Arctic Star Exploration, Blog
Relevium Selects 93,000 Sq. Ft Organic Cultivation Facility in Quebec
Momentum Public Relations
Press Release: June 4 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that, through its wholly-owned subsidiary Biocannabix (“BCX”), it has selected a 93,000 square foot facility in Montreal, Quebec with the objective of cultivating premium organic cannabis.
With the assistance of PipeDreemz Inc., Relevium has conducted initial assessment on the facility, a 93,000 Sq. Ft industrial building located adjacent to the TransCanada Highway, Trudeau International Airport and about 20 minutes from downtown Montreal. The building has been selected as a desirable location with a low risk profile for the application submission to Health Canada for an ACMPR cultivation license. Biocannabix will be leveraging the vast experience of lead consultant George Routhier and his company PipeDreemz Inc., a company with a remarkable 100% rate of success with ACMPR licensing from Health Canada.
Company Strategy
The strategy for the Company is to cultivate high quality organic strains for use in exclusive, high-end consumer packaged goods primarily for health and wellness. The Company will not compete on large scale supply, but rather plans to focus on custom niche and organic products with established partnerships for processing and ongoing research in cannabis derivatives.
The Company intends to develop the project in stages and expects to retrofit the building with an initial phase of 10,000 Sq. Ft of cultivation. Upon the completion of the first stage, successful operations and licensing, the company will then proceed with phases 2 and 3. Construction of the project is subject to financing and customary approvals.
Aurelio Useche, CEO of Relevium stated: “The strategy of Biocannabix will not be catered around being the lowest cost producer, but rather on being a premium and custom producer focused on consumer packaged goods to be sold through Relevium’s current and new brands.” Mr. Useche stated further: “The value in the supply chain will be in developing trusted, unique, ultra-premium product for luxurious brands.”
About PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Auxico Announces Discovery of Three Historical Mines at Zamora Silver-Gold Property, Sinaloa, Mexico
Momentum Public Relations
Press Release: June 1 2018
Auxico Resources Canada Inc. (CSE:AUAG) is pleased to announce that the Company has discovered three historical mines containing unrecognized shafts and pits located along the Zamora Vein, including the La Campeona mine, which returned 30 cm of 10.1 g/t gold and 941.7 g/t silver. These discoveries extend the Zamora Vein and the parallel El Obatel Vein over a strike length of at least 800 metres. The Zamora Silver-Gold Property located in Sinaloa, Mexico, and is 100% owned by Auxico Resources Canada.
|
The Company discovered a report that was written in 1982 by Antonio Flores Martinez and Marco Bustamante Yanez who were both employed at the time with the Consejo de Recursos Minerales (Mexican Council of Mineral Resources, “CRM”) and included all of the rehabilitation work done by the CRM on the Camichina Shaft, which gained access to the Los Olotes orebody. As well, this report documented all of the historic workings within a 1000m by 600m grid. Just recently, Auxico’s management found a map showing all of this information in the archives.
This map below provides information on three historic workings previously unknown, however well documented: El Tacomate, El Arroyito, and La Campeona. According to the information on the map, El Tacomate is located approximately 280m southwest of the Camichina Shaft along strike of the Zamora Vein where historic silver grades were in the kilograms per tonne and gold grades in several ounces per tonne. El Tacomate contains a 20cm wide sample of 0.70 g/t Au & 107.2 g/t Ag. El Arroyito, located about 325m southwest of La Camichina, returned 0.9m of 1.9 g/t Au & 413.3 g/t Ag. La Campeona, which is located on the north side of the Zamora River, returned 30cm of 10.1 g/t Au & 941.7 g/t Ag, almost a kg/t, which is not uncommon on the Property as has been previously tested and demonstrated by the Qualified Person in other areas within the Property limits. Of particular interest is the location of La Campeona, which coincides with some historical workings known as Rosa Maria, which the Company believes may be an old townsite, and a collapsed shaft indicating that mining was conducted here some time ago, and according to the structures, which still remain on surface, it appears to be from the early 1800’s and mined by the Spaniards. As well, there were signs of an Arrastra at Rosa Maria, which is a primitive mill for grinding and pulverizing gold or silver ore. The simplest form of the Arrastra is two or more flat-bottomed drag stones placed in a circular pit paved with flat stones, and connected to a center post by a long arm. This artisanal mill that would have been operational at that time processing the ore from underground, and a circular area with finely pulverized material are present beside what management believes to be a collapsed shaft. There are also historical workings on the south side of the Zamora River, which would indicate a possible strike length of the Zamora Vein for at least 800m. The El Obatel Vein, which is about 30m to the northwest of the Zamora Vein and parallel appears to extend for at least 700m along strike.
Auxico is anxious to conduct a detailed exploration and development campaign in this area, which would include substantial diamond drilling in order to prove up a resource along this 800m long silver-gold structure.
Qualified Person
This news release was reviewed and approved by Joel Scodnick, P.Geo., an independent consultant to Auxico, in his capacity as a Qualified Person, as defined by National Instrument 43-101.
ON BEHALF OF THE BOARD OF DIRECTORS
« signed »
Pierre Gauthier
Chairman & CEO, Auxico Resources Canada Inc.
Cell: +1 514 299 0881
About Auxico Resources Canada Inc.
Auxico Resources Canada Inc. (“Auxico”) is a Canadian company that was founded in 2014 and based in Montreal. Auxico is engaged in the acquisition, exploration and development of mineral properties in Colombia and Mexico.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
To view the maps associated with this press release, please visit the following links:
http://www.globenewswire.com/NewsRoom/AttachmentNg/3d7c184a-3747-4240-a0fe-5ae67ee6b529
http://www.globenewswire.com/NewsRoom/AttachmentNg/75675940-a93d-40bc-8f7d-98f9b0ec163d
- Published in Auxico Resources
Marijuana Stocks Still Have Legs
Momentum Public Relations
Blog: June 1 2018
Marijuana Stocks Still Have Legs
Bryan, Garnier & Co: Global Marijuana Market to Hit US$140 Billion by 2027
Canadian Licensed Producers Expanding Abroad
The exact date when recreational marijuana will be legalized is still uncertain. The Trudeau government has repeatedly said that it will be legalized this summer. When that great day comes to pass it may be the only time in Canadian history that the government has created an economic stimulus package that actually works: the legal marijuana industry.
Not content with only being valued in the billions of dollars in Canada, our domestic marijuana industry is also hell-bent on international expansion.
On January 28, 2018 the CBC ran a story quoting Bloomberg that said there were 87 publicly listed marijuana companies on the TSXV and that collectively they were worth US$37 billion. In January Statistics Canada estimated that almost 5 million Canadians spent $5.7 billion dollars buying marijuana, with only 10% of that going to legal medical cannabis.
On May 28, 2018 Aurora Cannabis announced that it had signed a distribution agreement with German plant based pharmaceutical distributor Heinrich Klenk. Klenk distributes its products in more than 25,000 drug stores across Germany and Europe. Klenk is a trusted name and Aurora has launched a new brand that will be produced in Canada named Cannabis Klenk which the company will distribute. Medical cannabis is legal in Germany.
Aurora has been making international plans and putting them into action for some time. It owns Berlin-based Pedanios, the leading marijuana importer, exporter and distributor of medical marijuana in the European Union as well as 51% of Aurora Nordic which plans on constructing a one million square foot greenhouse in Denmark. To round out its diversified activities the company also owns two companies that specialize in building greenhouse lighting systems, BC Northern Lights and Urban Cultivator.
Aurora is not alone on the international stage, Canopy Growth, which has Snoop Dogg as a spokesman, has operations in seven countries on four continents. Aphria Inc. has operations in more than 10 countries on five continents. It recently created a joint venture, Canninvest Africa with the South African Verve Group of Companies that will see it gain an interest in Verve Dynamics, a licensed producer of medical cannabis extracts, which it believes will become one of if not the lowest cost producer in the extract field.
Driven by economies of scale and the desire to have all the pieces to the puzzle in one place the industry has been consolidating for some time. The most recent example is the merger of Aurora and MedReleaf, which has created the largest marijuana company in the world.
If you think the market is now too high to buy in, you may want to think again. A story published in Forbes on March 1, 2018 predicts a robust and growing legal international marijuana poised for exponential growth.
The story is based on a report by Arcview Market Research which predicts that by 2027 spending on legal recreational and medical marijuana will hit US$57 billion with a 67% market share for recreational marijuana and a 33% share for medical cannabis.
The lion’s share of the revenues will be generated in North America where the largest recreational market is expected to develop with sales going from US$9.2 billion in 2017 to US$47 billion in 2027.
All of which means that serious investors should start doing their due diligence on the marijuana industry now, if they haven’t already. That due diligence should also include bio-pharmas that are developing cannabis- based drugs for regulatory approval and for the over the counter market.
If you still think that marijuana stocks are overpriced you may wish to consider this, investment bank Bryan, Garnier & Co have just predicted that the global marijuana market is poised to grow by a 1,000 percent to hit US$140 billion by 2027.
One of the more interesting set of statistics put out by Statista is that in America, medical marijuana will take a larger slice of the pie than recreational marijuana. The company predicts that by 2025 cannabinoid-based pharmaceuticals will be valued at US$13.2 billion and the legal recreational market at US$10.9 billion.
Whether or not cannabinoid-based pharmaceuticals will surpass the legal recreational market is as yet unknown but predictions like the one above are a sure indication that bio-pharmas launching successful drugs will be lucrative.
A rising tide raises all ships. When Canadian recreational marijuana legalization takes place marijuana stocks are expected to jump and by association so will those pharmaceutical companies developing successful cannabinoid-based drugs.
Tetra Bio-Pharma, (TSXV: TBP) is one such company with a pipeline of cancer chronic pain, and other products under development. Its lead product, PPP 001, trademarked as RX Princeps has started Phase 3 clinical trials and stands to be the first cannabinoid therapy that will have its efficacy and safety proved.
Once that happens, PPP 001 will very likely become the first drug to be given Health Canada and American FDA approval. This achievement will be marked by a Drug Identification Number, DIN, which means that it can legally be prescribed by doctors and eligible for insurance plan coverage. TBP already has distribution agreements in place in Israel and in Europe.
The above does not and should not be taken as investment advice. Investors have the responsibility of performing their own due diligence. In the interests of transparency, Momentum PR represents Tetra Bio-Pharma.
- Published in Blog